- Home
- ENFN vs COLL Comparison
ENFN vs COLL Comparison
Compare ENFN & COLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENFN
- COLL
- Stock Information
- Founded
- ENFN 1998
- COLL 2002
- Country
- ENFN United States
- COLL United States
- Employees
- ENFN N/A
- COLL N/A
- Industry
- ENFN Computer Software: Prepackaged Software
- COLL Biotechnology: Pharmaceutical Preparations
- Sector
- ENFN Technology
- COLL Health Care
- Exchange
- ENFN Nasdaq
- COLL Nasdaq
- Market Cap
- ENFN 1.1B
- COLL 1.0B
- IPO Year
- ENFN 2021
- COLL 2015
- Fundamental
- Price
- ENFN $11.50
- COLL $29.13
- Analyst Decision
- ENFN Hold
- COLL Strong Buy
- Analyst Count
- ENFN 5
- COLL 5
- Target Price
- ENFN $10.38
- COLL $43.60
- AVG Volume (30 Days)
- ENFN 1.0M
- COLL 304.0K
- Earning Date
- ENFN 03-11-2025
- COLL 02-27-2025
- Dividend Yield
- ENFN N/A
- COLL N/A
- EPS Growth
- ENFN N/A
- COLL 757.11
- EPS
- ENFN 0.03
- COLL 2.16
- Revenue
- ENFN $195,159,000.00
- COLL $599,245,000.00
- Revenue This Year
- ENFN $18.66
- COLL $13.25
- Revenue Next Year
- ENFN $17.25
- COLL $17.67
- P/E Ratio
- ENFN $543.67
- COLL $13.47
- Revenue Growth
- ENFN 15.78
- COLL 9.62
- 52 Week Low
- ENFN $7.83
- COLL $28.39
- 52 Week High
- ENFN $11.80
- COLL $42.29
- Technical
- Relative Strength Index (RSI)
- ENFN 66.62
- COLL 37.61
- Support Level
- ENFN $10.92
- COLL $29.39
- Resistance Level
- ENFN $11.80
- COLL $30.39
- Average True Range (ATR)
- ENFN 0.16
- COLL 1.00
- MACD
- ENFN -0.00
- COLL -0.24
- Stochastic Oscillator
- ENFN 65.91
- COLL 11.04
About ENFN Enfusion Inc.
Enfusion Inc is a software-as-a-service (SaaS) provider focused on transforming the investment management industry. Its solutions are designed to eliminate technology and information barriers, empowering investment managers to make and execute an informed investment decisions in real-time. It simplifies investment and operational workflows by unifying mission-critical systems and coalescing data into a single dataset resulting in a single source of truth. It generates maximum revenue from Americas, followed by Asia Pacific and Europe, Middle East, and Africa.
About COLL Collegium Pharmaceutical Inc.
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.